Trials / Unknown
UnknownNCT02045654
Platelet Response During the Second Cycle of Decitabine Can Predict Response and Survival for Myelodysplastic Syndrome
Retrospective Study for Predictive Marker for Decitabine Treament in MDS Patients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 1 (estimated)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy of decitabine and identify predictors for response to decitabine therapy.
Detailed description
* Histologically confirmed Myelodysplastic syndrome Diagnosed with MDS (de novo or secondary) based on the World Health Organization (WHO) classifications * Survival and response Analysis * Response rate * Overall survival * Leukemia free survival
Conditions
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2014-02-01
- Completion
- 2015-03-01
- First posted
- 2014-01-27
- Last updated
- 2014-01-27
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02045654. Inclusion in this directory is not an endorsement.